New pill hopes to quiet Parkinson's – but It's early days
NCT ID NCT07142044
First seen Jun 26, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This early-stage trial tests whether an oral drug called EC5026 is safe and might ease symptoms in 18 adults with Parkinson's disease. Participants take the drug or a placebo daily for 28 days, with frequent checkups and tests. The main goal is safety, with symptom improvement explored as a secondary aim.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- EC5026 oral tablet
- What this could lead to
- If it works, this could point toward a new way to ease Parkinson's symptoms by targeting inflammation pathways.
- What could go wrong
- This is a very early, small trial (18 people) focused on safety, not proof of effectiveness. The drug may not improve symptoms or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE (PD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California Davis
RECRUITINGSacramento, California, 95817, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a mediterranean diet and exercise ease Parkinson's by reshaping the gut?
- CBD oil shows promise for easing anxiety and depression in Parkinson's patients
- Could a Brain-Healthy diet help fight ALS and Parkinson's?
- Parkinson's treatment could go monthly: new injection tested
- Smartphone beats could steady Parkinson's steps
- Parkinson's patients get new hope: group therapy targets anxiety and depression